Synovics Pharmaceuticals, Inc.
SYVC
$0.00
$0.000.00%
OTC PK
| 07/31/2009 | 04/30/2009 | 01/31/2009 | 10/31/2008 | 07/31/2008 | |
|---|---|---|---|---|---|
| Revenue | -79.54% | -54.11% | 60.66% | 47.68% | 12.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.54% | -54.11% | 60.66% | 47.68% | 12.12% |
| Cost of Revenue | -54.17% | -27.28% | 37.77% | 19.13% | 9.61% |
| Gross Profit | -119.28% | -98.79% | 135.95% | 175.98% | 16.29% |
| SG&A Expenses | -70.16% | -41.79% | 62.83% | -30.48% | -19.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.49% | -31.07% | 42.39% | -2.64% | -6.42% |
| Operating Income | -141.21% | -111.73% | 36.04% | 110.70% | 64.77% |
| Income Before Tax | -512.68% | 11.85% | 50.51% | 115.85% | 106.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -512.68% | 11.85% | 50.51% | 115.85% | 106.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -512.68% | 11.85% | 50.51% | 115.85% | 106.54% |
| EBIT | -141.21% | -111.73% | 36.04% | 110.70% | 64.77% |
| EBITDA | -166.47% | -130.62% | 43.28% | 119.44% | 69.78% |
| EPS Basic | -493.02% | 35.08% | 58.94% | 111.67% | 106.81% |
| Normalized Basic EPS | 11.32% | 35.13% | 58.81% | 112.74% | 35.71% |
| EPS Diluted | -800.00% | 35.08% | 58.94% | 111.67% | 103.96% |
| Normalized Diluted EPS | -35.14% | 35.13% | 58.81% | 112.74% | 57.82% |
| Average Basic Shares Outstanding | 4.92% | 35.86% | 20.37% | 35.77% | -3.97% |
| Average Diluted Shares Outstanding | -31.27% | 35.86% | 20.37% | 35.77% | 46.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |